pharmaphorum19h
A Pfizer consumer buyout won't detract from pharma business, says GSK chief
GlaxoSmithKline would consider buying Pfizer’s consumer health business – but only if the price is right, according to the company's chief executive. Emma Walmsley has also been busy shaking ...
pharmaphorum6d
Pfizer could fetch $15bn for consumer health business
These include GlaxoSmithKline, though it is already looking to buy Novartis out of its joint venture in consumer health for around £8bn ($10.5bn). Others include Reckitt Benckiser, Procter ...
The Financial Express6y
GlaxoSmithKline Consumer Healthcare rated ‘hold’; Q2 FY19 results surpassed expectations
GSK Consumer’s (GSK’s) Q2FY19 revenue, Ebitda and PAT growth of 14%, 35% and 43% y-o-y, respectively, surpassed estimates. This was the fourth consecutive quarter of strong volume spurt ...
HUL receives ₹962 crore tax notice over TDS dispute GlaxoSmithKline deal
HUL finalized its merger with GlaxoSmithKline Consumer Healthcare Limited (GSKCH) in 2020, after receiving the required ...
Barclays Remains a Hold on GlaxoSmithKline (GSK)
In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target ...
GlaxoSmithKline: Sell Rating Amidst Weak Vaccine Performance and Projected EPS Decline
GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from ...
Business Insider India6y
Pharma giant GlaxoSmithKline signs mega deal with Pfizer that could change the face of global healthcare
GlaxoSmithKline will combine its consumer health business with Pfizer - split at 68% to 32% in equity holdings respectively - and its shares rose as much as 7.4% on the announcement. GSK is ...